Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
28 août 2018 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
27 juin 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Inc. Announces New CEO
12 juin 2018 08h32 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H....
Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
04 juin 2018 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
01 juin 2018 16h11 HE
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
14 mai 2018 09h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with...
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
11 mai 2018 16h10 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
18 avr. 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
04 avr. 2018 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a...